

Biotech Financing Update

March 2018 – May 2018



UK BioIndustry Association



Biotech Financing Update

Overall figures

These figures capture the biotech financing data from 1 March 2018 – 31 May 2018. As we moved into the second quarter of the year we saw a big increase in venture capital fundraisings and the first Initial Public Offering (IPO) of the year.


Follow on financings cooled in this period following a very strong first quarter, but did see a return to follow on financing on London's Main Market.

IPO	All other public financings	Venture Capital
Q2 2018 £36 MILLION	Q2 2018 £64.85 MILLION	Q2 2018 £329.6 MILLION
Q1 2018 £0 MILLION	Q1 2018 £265.5 MILLION	Q1 2018 £134.9 MILLION
TOTAL 2018 to date £36 MILLION	TOTAL 2018 to date £330.35 MILLION	TOTAL 2018 to date £464.5 MILLION
TOTAL 2017 £234 MILLION	TOTAL 2017 £452 MILLION	TOTAL 2017 £515 MILLION

Venture capital funding

Venture capital funding figures really rose as we moved into the second quarter of the year with the majority of funding going to post B rounds. All companies with major fundraisings are BIA members. A large part of the post B funding is the impressive £100 million fund raising by Oxford Nanopore.

UK VC Progression



Top UK VC Rounds

Company Name	Round	£m
Oxford Nanopore Technologies	Not disclosed	100
Benevolent AI	Not disclosed	84.5
Crescendo Biologics	Series B	57
Enterprise Therapeutics	Series B	29

Source: Informa - Strategic Transactions and Scrip

IPOs

2018 continues to have a slow start on IPOs for UK biotech companies, but we have seen the first biotech IPO of the year, with a £36 million fundraising from Acacia Pharma group on Euronext in Brussels. We will continue to monitor if more UK companies choose to launch on the European exchanges rather than the UK or US.



£36m

fundraising
from Acacia
Pharma group
on Euronext
in Brussels

Biotech Financing Update

Follow on financings

The first set of results for 2018 was impacted by the large follow on financing from GW pharma on Nasdaq. Although the figures are not as high in this round, it is good to see UK biotech companies raising money from follow on financings on both AIM and the Main Market. The Main Market figure is also more than four times the total raised in follow on financings on the main market in 2017.



Oxford Biomedica	(£20.5m, Main Market, March 3)
-------------------------	--------------------------------

Summit Therapeutics	(£15m, AIM, March 27)
----------------------------	-----------------------

Diurnal Group	(£11.5m, AIM, April 3)
----------------------	------------------------

Motif Bio	(£7.35m, AIM, May 17)
------------------	-----------------------

Ixico	(£5.5m, AIM, May 3)
--------------	---------------------

Scancell Holdings	(£5, AIM, May 8)
--------------------------	------------------

Follow on financing by market

	Q2	Q1
Main Market follow on	20.5	0
AIM follow on	44.35	43.9
Nasdaq follow on	0.0	221.6
Total	64.85	£265.5

Source: Informa - Strategic Transactions and Scrip

Debt financing

Only one UK company has accessed debt financing in this round of data -Sinclair Pharma - and current debt financing levels mean that the same total amount as 2017 is likely to be accessed in 2018.



Region	Debt* total £m	Count	Average £m
Canada	771	3	290
San Diego	567	3	189
Colorado	305	2	152
Maryland	261.3	2	130.6
Arizona	150	1	150
Massachusetts	103.6	1	103.6
France	47.8	3	15.9
San Francisco	39.7	3	13.2
UK	20.5	1	20.5

Source: Informa - Strategic Transactions and Scrip

www.bioindustry.org
pharmaintelligence.informa.com

BIA Supporters



horizon
INSPIRED CELL SOLUTIONS

Johnson & Johnson INNOVATION

lifeArc

VWR
We Enable Science

Arthur J. Gallagher
BUSINESS WITHOUT BARRIERS™

BIA
UK BioIndustry Association